Mainz Biomed B.V. (MYNZ) Price & Analysis

Compare

365 Followers

MYNZ Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.30 - $16.36

Previous CloseN/A

Volume20.13K

Average Volume (3M)148.69K

Market Cap

$7.69M

Enterprise ValueN/A

Total Cash (Recent Filing)$6.24M

Total Debt (Recent Filing)$3.27M

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Sep 03, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding4,577,853

10 Day Avg. Volume85,096

30 Day Avg. Volume148,688

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$14.00

Price Target Upside733.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Innovative TechnologyThe company's Next Generation Test leverages mRNA biomarkers to expand the ability to detect pre-cancerous advanced adenomas (AAs), enabling prevention of CRC.

Market OpportunityExisting tests with a similar format, such as Cologuard, have achieved commercial success with over $2B in annual sales, presenting an opportunity for Mainz Biomed to capture share.

Strategic CollaborationsAn agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.

Bears Say

Competitive PressureMainz Biomed is entering a market where existing tests, like Cologuard, have already set a high commercial benchmark with over $2B in annual sales.

Mainz Biomed B.V. News

Mainz Biomed receives Swiss regulatory approval to market ColoAlert

Mainz Biomed (MYNZ) announces that ColoAlert, its non-invasive colorectal cancer screening test, has been officially registered and approved...

19d ago

MYNZ

Mainz Biomed Secures $3 Million Through Securities Purchase Agreement

Mainz Biomed B.V. ( ($MYNZ) ) has provided an update. Mainz Biomed N.V., a company involved in the...

27d ago

MYNZ

Mainz Biomed files to sell 1.47M ordinary units

16:44 EDT Mainz Biomed (MYNZ) files to sell 1.47M ordinary units Published first on TheFly – the ultimate...

1M ago

MYNZ

Mainz Biomed, CARE announce collaboration agreement

Mainz Biomed (MYNZ) announced a collaboration with CARE diagnostica Laborreagenzien, CARE. CARE is currently working with more than...

1M ago

MYNZ

Mainz Biomed reviews accomplishments for first half of 2025

Mainz Biomed (MYNZ) reviewed its major accomplishments of the first six months ending June 30, 2025, and provided...

2M ago

MYNZ

Mainz Biomed secures public funding to advance pancreatic cancer screening test

Mainz Biomed (MYNZ) announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank...

2M ago

MYNZ

Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating

Mainz Biomed B.V. (MYNZ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst...

3M ago

MYNZ

Mainz initiates feasibility study of biomarker panel in PancAlert project

Mainz Biomed (MYNZ) announces the commencement of the next phase in its PancAlert project, a research initiative focused...

3M ago

MYNZ

Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting

Mainz Biomed B.V. ( ($MYNZ) ) has shared an announcement. On June 2, 2025, Mainz Biomed N.V. held...

3M ago

MYNZ

Mainz Biomed N.V. Secures $4 Million Through Securities Offering

The latest announcement is out from Mainz Biomed B.V. ( ($MYNZ) ). Mainz Biomed N.V. announced on May...

3M ago

MYNZ

Mainz Biomed prices $4.0M offering of common stock at $2.00 per unit

Maxim Group LLC is acting as the sole placement agent for the offering. Published first on TheFly –...

3M ago

MYNZ

Mainz Biomed announces interim read out for eAArly DETECT 2 study

Mainz Biomed (MYNZ) announced that it intends to provide an interim read out of its eAArly DETECT 2...

4M ago

MYNZ

Mainz Biomed files to sell 2.45M ordinary units

Maxim Group is acting as manager. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

4M ago

MYNZ

Mainz Biomed Prepares for June 2025 Annual General Meeting

Mainz Biomed B.V. ( ($MYNZ) ) has provided an update. On May 13, 2025, Mainz Biomed N.V. plans...

4M ago

MYNZ

MYNZ FAQ

What was Mainz Biomed B.V.’s price range in the past 12 months?

Mainz Biomed B.V. lowest stock price was $1.30 and its highest was $16.36 in the past 12 months.

What is Mainz Biomed B.V.’s market cap?

Mainz Biomed B.V.’s market cap is $7.69M.

When is Mainz Biomed B.V.’s upcoming earnings report date?

Mainz Biomed B.V.’s upcoming earnings report date is Sep 03, 2025 which is in 2 days.

How were Mainz Biomed B.V.’s earnings last quarter?

Currently, no data Available

Is Mainz Biomed B.V. overvalued?

According to Wall Street analysts Mainz Biomed B.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mainz Biomed B.V. pay dividends?

Mainz Biomed B.V. does not currently pay dividends.

What is Mainz Biomed B.V.’s EPS estimate?

Mainz Biomed B.V.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Mainz Biomed B.V. have?

Mainz Biomed B.V. has 4,577,853 shares outstanding.

What happened to Mainz Biomed B.V.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Mainz Biomed B.V.?

Currently, no hedge funds are holding shares in MYNZ

Company Description

Mainz Biomed B.V.

Mainz Biomed B.V. (MYNZ) is a biotechnology company focused on the development and commercialization of diagnostic solutions for the early detection of cancer. The company operates primarily in the healthcare and biotechnology sectors, leveraging cutting-edge molecular genetic testing technologies to provide non-invasive, patient-friendly diagnostic tools. Their flagship product is a colorectal cancer screening test designed to detect cancerous and precancerous conditions through advanced DNA analysis.

Mainz Biomed B.V. (MYNZ) Earnings & Revenues

Historic Earnings Reports

MYNZ Stock 12 Month Forecast

Average Price Target

$14.00

▲(733.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","81":"$81","20.25":"$20.3","40.5":"$40.5","60.75":"$60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,20.25,40.5,60.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,2.3876923076923076,3.355384615384615,4.323076923076924,5.2907692307692304,6.258461538461539,7.226153846153847,8.193846153846154,9.161538461538463,10.12923076923077,11.096923076923078,12.064615384615385,13.032307692307693,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,2.3876923076923076,3.355384615384615,4.323076923076924,5.2907692307692304,6.258461538461539,7.226153846153847,8.193846153846154,9.161538461538463,10.12923076923077,11.096923076923078,12.064615384615385,13.032307692307693,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.42,2.3876923076923076,3.355384615384615,4.323076923076924,5.2907692307692304,6.258461538461539,7.226153846153847,8.193846153846154,9.161538461538463,10.12923076923077,11.096923076923078,12.064615384615385,13.032307692307693,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.8,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.97,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.32,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >